Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the safety and efficacy of Multiple Target Kinase
Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody in subjects with
advanced thyroid cancer.